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We are glad to know that our manuscript is almost ready for the publication. As indicated in the 
editorial comment, we revised abstract as follows:
Abstract (218 words)
Objectives
To assess trial-level factors associated with the contribution of individual participant data (IPD) 
to IPD meta-analyses, and to quantify the data availability bias, namely the difference between 
the effect estimates of trials contributing IPD and those not contributing IPD in the same 
systematic reviews (SRs).
Design and Setting
We included SRs of randomized controlled trials (RCTs) with IPD meta-analyses since 2011. We 
extracted trial-level characteristics and examined their association with IPD contribution. To 
assess the data availability bias, we retrieved odds ratios from the original RCT papers, 
calculated the ratio of odds ratios (RORs) between aggregate data (AD) meta-analyses of RCTs 
contributing IPD and those of RCTs not contributing IPD for each SR, and meta-analytically 
synthesized RORs. 
Results
Of 728 eligible RCTs included in 31 SRs, 321 (44%) contributed IPD, while 407 (56%) did not. A 
recent publication year, larger number of participants, adequate allocation concealment, and 
impact factor ≥10 were associated with IPD contribution. We found the SRs yielded widely 
different estimates of RORs. Overall, there was no significant difference in the pooled effect 
estimates of AD meta-analyses between RCTs contributing and not contributing IPD (ROR 1.01, 
95% confidence interval 0.86–1.19). 
Conclusions
There was no consistent evidence of a data availability bias in recent IPD meta-analyses of RCTs 
with dichotomous outcomes. Higher methodological qualities of trials were associated with IPD 
contribution. 
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To assess trial-level factors associated with the contribution of individual 
participant data (IPD) to IPD meta-analyses, and to quantify the data 
availability bias, namely the difference between the effect estimates of 
trials contributing IPD and those not contributing IPD in the same 
systematic reviews (SRs).
Design and Setting
We included SRs of randomized controlled trials (RCTs) with IPD meta-
analyses since 2011. We extracted trial-level characteristics and examined 
their association with IPD contribution. To assess the data availability bias, 
we retrieved odds ratios from the original RCT papers, calculated the ratio 
of odds ratios (RORs) between aggregate data (AD) meta-analyses of 
RCTs contributing IPD and those of RCTs not contributing IPD for each 
SR, and meta-analytically synthesized RORs. 
Results
Of 728 eligible RCTs included in 31 SRs, 321 (44%) contributed IPD, 
while 407 (56%) did not. A recent publication year, larger number of 
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participants, adequate allocation concealment, and impact factor ≥10 were 
associated with IPD contribution. We found the SRs yielded widely 
different estimates of RORs. Overall, there was no significant difference in 
the pooled effect estimates of AD meta-analyses between RCTs 
contributing and not contributing IPD (ROR 1.01, 95% confidence interval 
0.86–1.19). 
Conclusions
There was no consistent evidence of a data availability bias in recent IPD 
meta-analyses of RCTs with dichotomous outcomes. Higher 
methodological qualities of trials were associated with IPD contribution. 
Keywords
Individual participant data, systematic review, meta-analysis, data availability bias
What is new?
Key findings
・ Trial-level characteristics such as a recent year of publication, large number of 
participants, high impact factor, and adequate allocation concealment were 
independently associated with individual participant data (IPD) contribution to 
systematic reviews (SRs) with IPD meta-analyses. 
・ We could not find consistent evidence of a data availability bias; the effect 
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estimates of trials contributing IPD were not statistically different from those not 
contributing IPD in the same systematic reviews (SRs).
What this study adds to what was known?
・ Methodological qualities of trials were associated with the contribution of IPD to 
IPD meta-analysis, but effect estimates might not affect this result.
・ While previous studies suggested the presence of a data availability bias only 
narratively or theoretically, we systematically compared the effect estimates 
between studies with and without IPD contribution and showed that there was no 
consistent evidence of a data availability bias.
What is the implication and what should change now?
 Investigators should be aware of the differences in methodological qualities 
between RCTs with and without IPD contribution when conducting IPD meta-
analyses.
 While we did not detect any systematic data availability bias in the recednt IPD 
meta-analyses, effect estimates in some IPD meta-analyses might still be biased in 
either direction due to the data availability.
Background
 Individual participant data (IPD) meta-analyses are considered to increase the 
statistical power of systematic reviews (SRs) as well as enable more valid subgroup 
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analyses, in comparison with meta-analyses that are based on aggregate data (AD) 
extracted from published trial reports [1-3]. Encouragement to share IPD from clinical 
studies has risen in the scientific literature, and the number of SRs with IPD meta-
analyses has increased dramatically over the past few years [4-9]. 
 However, SRs with IPD meta-analyses require the review authors to spend substantial 
time and effort to contact and request IPD from the authors of the original studies [1, 
10, 11] with no certainty that all original authors will contribute their data. Indeed, only 
25% of the 760 IPD meta-analyses conducted between 1987 and 2015 retrieved 100% 
of the data from the relevant trials, and 43% retrieved 80% of the data of relevant trials 
[10].
The risk of data availability bias increases when all IPD data cannot be procured [2, 
10, 12, 13]. The data sharing policy of RCTs might be influenced by the views of the 
investigators, as well as by the resources or results of the RCTs [5]. If unavailability of 
IPD is associated with the direction or the size of the intervention effect, studies that are 
available for IPD analyses may not be representative of the whole evidence, and the 
results of such IPD meta-analyses may be misleading. However, the difference in 
characteristics between RCTs contributing and not contributing IPD has not been 
investigated. 
 To date, data availability bias has been discussed only anecdotally, narratively or 
theoretically and there has been no systematic examination aiming to quantify the 
impact of this bias on the effect estimates of meta-analyses [2, 6, 10, 13, 14]. The 
purposes of this study were, therefore, two-fold: (i) To assess RCT-level factors 
associated with the contribution of IPD, and (ii) to examine data availability bias in IPD 






All therapeutic RCTs included in SRs that fulfilled all following criteria were eligible: 
(i) SRs with IPD meta-analyses, (ii) SRs that included only RCTs comparing an active 
intervention against a control condition in terms of a dichotomous outcome, (iii) SRs 
that reported a full reference list of the included RCTs, and (iv) SRs published in 
English. We excluded the following SRs: (v) SRs published before 2011, (vi) SRs 
where all included RCTs provided IPD data, (vii) SRs of diagnostic or prognostic 
studies, and (viii) SRs with network meta-analyses. A cutoff year of 2011 was selected 
because a reporting guideline for SRs, Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses: The PRISMA Statement, was first published in 2009 [15]. 
We allowed two years for the dissemination of this guideline.
Search methods
We used the reference list from a recent comprehensive review of IPD meta-analyses 
conducted by Nevitt et al[10]. We also performed an updated search of MEDLINE via 
Ovid using the same search strategy as the above review to identify relevant SRs as of 
10th March 2018. Supplementary file 1 shows the search terms we used.
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Study selection
　Two pairs of researchers (YT-TF and KO-AO) independently screened the titles and 
abstracts of articles identified by the updated search. We pooled the potentially eligible 
SRs and the reference list from the review conducted by Nevitt et al [10]. We then 
independently assessed eligibility based on a full-text review.
Data extraction
　Eight researchers (YT, TF, KO, AO, ST, TI, YL and CP) independently extracted the 
following RCT-level factors from the included RCTs; year of publication, sample size, 
whether the primary outcomes of the RCT was positive or not, allocation concealment, 
industrial sponsorship, publication status (full-publication or not), data sharing 
statement (available, unavailable, or unclear), journal impact factor (IF), and language. 
We selected the primary outcomes of the RCTs using the following hierarchy: an 
outcome that was mentioned (1) as primary, (2) in the title, (3) in the objective, (4) first 
in the abstract, (5) first in the text. We defined the primary outcome as positive when 
the selected primary outcome was statistically significant in superiority trials or within 
the noninferiority margin in noninferiority trials. We chose not blinding but adequate 
allocation concealment as a marker of study quality because the feasibility of blinding 
and its impact on outcomes varies across research questions. We used the IF of the 
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journal from 2017 Journal Citation Reports® Science Edition (Thomson Reuters, 2018) 
and assigned an IF of zero to conference abstracts and unpublished studies. 
 We also extracted the following SR-level factors from the included SRs: year of 
publication, the number of included RCTs, types of review (pharmacological or non-
pharmacological interventions, adult or pediatric, and Cochrane or non-Cochrane), and 
funding (yes/no).
 To examine any discrepancy between the effect estimates of RCTs contributing IPD 
(C-RCTs) and those not contributing IPD (NC-RCTs), we selected a single outcome per 
SR. As the SR might have reported several outcomes, we selected the single primary 
outcome that fulfilled all the following criteria: (1) An efficacy outcome measured as a 
pooled risk ratio (RR) or odds ratio (OR), (2) Not a composite outcome, and (3) Not an 
outcome of adverse events or subgroup analysis. We did not adopt a composite outcome 
because the definition or components of the outcome was expected to vary across trials. 
In cases where the primary outcome did not meet these criteria, we adopted the outcome 
with the largest number of trials or the first outcome described which met these criteria.
　For the single selected outcome in each SR, we extracted the number of events and 
participants in the intervention and control groups from the original published journal 
articles or conference abstracts of both C-RCTs and NC-RCTs. If the number of events 
or participants was missing, or if the selected outcome was not reported in the original 
RCT but provided in the IPD meta-analysis, we imputed them from the information or 
outcome data presented in the IPD-SR. We also extracted the pooled RR or OR from 
the reported IPD meta-analysis. We converted the pooled RR to OR using the observed 
control event rate [16].
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Statistical analysis
We first described RCT characteristics, each classified by whether the RCT contributed 
IPD to the SR or not. We then explored the RCT-level factors (see Data Extraction) 
associated with the contribution of IPD using univariable mixed-effect logistic 
regression with a random intercept for SRs to account for the clustering effects of RCTs 
within each SR, and a multivariable mixed-effects logistic regression model with fixed 
factors (year of publication, sample size, positive primary outcome [yes or no], adequate 
allocation concealment [yes or no], industrial sponsorship [yes or no], publication status 
[full-publication or not], data sharing statement [available or not), IF [no IF, < 5, 5 ≤ to 
< 10, or 10 ≤], language [published in English or not] ), and a random intercept for SRs. 
 We calculated odds ratios using the number of events and the number of patients 
aggregated from the original RCT papers and pooled them in aggregate data (AD) meta-
analyses using random-effects models. Each OR was recalculated so that an OR <1 
indicated that the intervention arm was favored. To assess data availability bias 
quantitatively, we calculated and pooled the ratio of odds ratios (ROR) in AD meta-
analyses of C-RCTs to those in AD meta-analyses of NC-RCTs using the following 
two-step approach proposed by Sterne et al [17]. First, we estimated an ROR in each 
AD meta-analysis by using a random-effect meta-regression. An ROR <1 indicated a 
larger treatment effect estimate in AD meta-analyses of C-RCTs than in NC-RCTs. We 
estimated the combined ROR across SRs and the 95 % confidence interval (CI) with a 
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random-effects meta-analysis model. We used the I2 statistic, τ2 –statistic and 95% 
prediction interval to quantify the heterogeneity between SRs. 
We expressed continuous variables as mean (standard deviation) for normally 
distributed data or median (interquartile range [IQR]) for non-normally distributed data 
and categorical variables as numbers with the percentage. We considered a two-sided p 
value < 0.05 as a statistically significant difference. We used Stata/SE, V.14.0  
(StataCorp, College Station, TexasX, USA) for all analyses.
Sensitivity analysis
 To examine the robustness of the estimated ROR, we performed the following 
sensitivity analyses. First, we adjusted SR-level factors (year of publication, the number 
of included studies, types of review [Cochrane or non-Cochrane, pharmacological or 
not, and pediatric or not], or funding) that assumed to be confounders of the association 
between IPD contribution and the ROR using the meta-regression model. Second, we 
excluded RCTs for which we imputed the results of AD meta-analysis with those 
reported in IPD meta-analysis. Third, we examined a discrepancy between IPD meta-
analytic results of C-RCTs and AD meta-analytic results of NC-RCTs using the same 
methods for the primary outcome. 
Additional analyses
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As a post-hoc analysis, we used log-transformed data of the number of randomized 
participants and impact factors instead of categorized data, and added them into the 
mixed effects multivariable model to examine their associations with the contribution of 
IPD. 
The study was registered in UMIN-CTR as UMIN000028325 
(https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000036147). 
Results
Results of searches 
 Figure 1 shows the flow diagram of the present study. We identified 2349 possible 
SRs with IPD meta-analyses including 102 references from the previous study [10]. We 
assessed the eligibility of 268 SRs with IPD meta-analyses that remained after screening 
of titles and abstracts, and included 37 IPD-SRs for a total of 728 RCTs. For the 
assessment of data availability bias, six SRs had only one or two RCTs that reported the 
selected outcome, which made it impossible to calculate the ROR using a random 
effects meta-regression model. Among 631 RCTs included in the remaining 31 SRs, 
264 did not report the selected outcome. Consequently, we included 367 RCTs that 
reported the selected outcome in the analysis for data availability bias. 
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Characteristics of included IPD systematic reviews
Supplementary file 2 shows the characteristics of the included IPD-SRs. The number of 
included RCTs in the IPD-SRs varied from 5 to 103 (median 13, IQR 11 to 21), and the 
IPD retrieval rate ranged from 10 % to 92 % (median 71 %, IQR 50 % to 81 %). 
Twenty-five (68 %) IPD-SRs had funding, 21 (57 %) focused on pharmacological 
interventions, 7 (19%) were Cochrane reviews, and 2 (5 %) were in pediatric areas. 
Characteristics of included studies and IPD contribution
 Of 728 RCTs included, 321 contributed IPD and 407 did not. Table 1 summarizes the 
characteristics of the included RCTs and the association with the IPD contribution. C-
RCTs were likely to have a recent year of publication, a larger sample size, adequate 
allocation concealment, full publication status, higher impact factor, and sponsorships 
as compared to NC-RCTs. We next examined the association between RCT 
characteristics and IPD contribution with logistic regressions. As shown in Table 1, a 
recent publication year, larger number of participants randomized, adequate allocation 
concealment, and high impact factor (≥10) compared to IF <5 were independently 
associated with IPD contribution. On the other hand, whether the primary outcomes 
were positive was not associated with IPD contribution (adjusted OR 1.06, 95% CI 0.72 
to 1.55). The association of the number of randomized participants or that of impact 
factors with IPD contribution remained unchanged when we used log-transformed data 
instead of categorized data (OR 1.34, 95% CI 1.07 to 1.69, and OR 1.28, 95% CI 1.03 
to 1.58, respectively)
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Table 1 Characteristics of included RCTs and the associations with IPD contribution




Years since publication, mean (SD) 10.0 (6.9) 11.4 (8.9) 0.94 (0.92 to 0.97) 0.96 (0.93 to 0.99)
Number of randomized participants
  1st quartile 12 to 101 5 to 60 Ref Ref
  2nd quartile 102 to 228 60 to 115 1.85 (1.12 to 3.06) 1.54 (0.90 to 2.63)
  3rd quartile 228 to 619 116 to 250 2.89 (1.71 to 4.90) 1.90 (1.07 to 3.37)
  4th quartile 620 to 20536 250 to 17354 5.09 (2.83 to 9.15) 2.28 (1.16 to 4.47)
Adequate allocation concealment 230 (57) 107 (33) 3.34 (2.27 to 4.91) 2.33 (1.53 to 3.55)
Publication status
  Full publication 375 (92) 281 (88) Ref Ref
  Conference abstract 23 (6) 35 (10) 0.37 (0.9 to 0.71) 0.82 (0.27 to 2.51)
  Unpublished 9 (2) 5 (2) 0.66 (0.18 to 2.38) n/a‡
Impact factor§
  <5 142 (35) 161 (50) Ref Ref
  ≥5 to <10 66 (16) 42 (13) 1.57 (0.93 to 2.65) 1.52 (0.87 to 2.65)
  ≥10 152 (37) 48 (15) 3.13 (1.86 to 5.24) 2.18 (1.22 to 3.88)
  No impact factor 47 (12) 70 (22) 0.59 (0.35 to 1.00) 0.84 (0.33 to 2.14)
Industrial sponsorship 119 (29) 68 (21) 2.13 (1.32 to 3.45) 1.40 (0.84 to 2.34)
Published in English 399 (98) 307 (96) 2.29 (0.77 to 6.81) 0.99 (0.26 to 3.81)
Statement to share the data 4 (1) 3 (1) 1.03 (0.19 to 5.56) 0.61 (0.10 to 3.80)
Positive results in the primary 
outcome‖‖ 216 (55) 148 (47) 1.16 (0.82 to 1.66) 1.06 (0.72 to 1.55)
Note: Values for categorical variables and continuous variables are given as number (percentage) and mean (SD) 
or median (IQR). *Using univariable mixed effects logistic regression with a random intercept for the systematic 
review. †Using multivariable mixed effects logistic regression model with fixed factors (year of publication, 
sample size, adequate allocation concealment, publication status (full-publication or not), impact factor (no 
impact factor, < 5, 5 ≤ to < 10, or 10 ≤), industrial sponsorship, language (written in English or not), data sharing 
statement (available or not) and whether the primary outcomes in the RCTs were positive) and a random intercept 
for the systematic review. ‡No sufficient data was available to conduct the multivariable analysis §Impact factor 
in 2017. We assigned an impact factor of zero to conference abstracts and unpublished studies. ‖‖Any of the 
primary outcomes were positive when the selected primary outcome was statistically significant in efficacy trials 
or within the noninferiority margin in noninferiority trials. Abbreviations: RCT, randomized controlled trial; IPD, 
individual participant data; C-RCT, RCTs contributing IPD; NC-RCT, RCTs not contributing IPD; SD, standard 
deviation; IQR, interquartile range.
Data availability bias
 Figure 2 shows the RORs that compared AD meta-analyses of C-RCTs and those of 
NC-RCTs among 31 SRs including 377 RCTs. We found the SRs yielded widely 
different estimates of RORs. For example, one SR showed a significantly large 
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treatment effect in C-RCTs compared with NC-RCTs [18], whereas one SR showed a 
significantly small effect of C-RCTs compared with NC-RCTs [19]. The remaining 29 
SRs showed a non-significant difference in treatment effects between C-RCTs and NC-
RCTs. Overall, we found no statistically significant association between IPD 
contribution and the size or direction of treatment effects which could be estimated from 
AD meta-analyses of the trials within each SR (pooled ROR 1.01, 95 % CI 0.86 to 1.19, 
I2 = 27 %, τ2 = 0.044, and 95% prediction interval 0.60 to 1.42) (Fig 2). 
Sensitivity analyses
A sensitivity analysis excluding the data imputed from the IPD meta-analysis showed a 
consistent result (pooled ROR 1.02, 95% CI 0.85 to 1.22, I2 = 34 %, τ2 = 0.064, and 
95% prediction interval 0.52 to 1.51). The univariable meta-regression analyses showed 
that there were no statistically significant associations between any of the SR-level 
factors and the ROR (Supplementary file 3). There was no statistically significant 
difference between IPD meta-analytic results of C-RCTs and AD meta-analytic results 
of NC-RCTs (ROR 1.11, 95% CI 0.83 to 1.48, I2 = 47 %, τ2 = 0.132, and 95% 




 RCT features reflecting the high methodological quality of RCTs, such as a large 
number of participants, IF ≥ 10, and adequate allocation concealment, were 
independently associated with IPD contribution. However, we could not find consistent 
evidence of data availability bias due to IPD contribution in recent SRs with IPD meta-
analyses. 
Context with prior studies
 Our findings of the RCT characteristics associated with IPD sharing are mostly in line 
with those from previous studies in the literature. We found that low quality RCTs, that 
had unclear or high risk of bias in participant selection and had lower impact, might be 
less likely to provide IPD. A previous research reported a higher prevalence of apparent 
errors, i.e. low quality, in the reporting of statistical results was associated with authors’ 
reluctance to share research data in high-ranked psychology journals [20]. In addition, 
old studies might not provide IPD due to limited access to the trial data [21]. These 
previous findings, however, were based on a univariable analysis. We comprehensively 
investigated the RCT factors associated with data sharing and examined if the study 
quality made an independent contribution using a multivariable model. Our data also 
showed that such trends persisted in more recent cohorts.
 Previous studies have raised concerns about data availability bias in effect estimates of 
meta-analyses using IPD. [2, 10, 13]. For example, a prior study showed a discrepancy 
of 20% in reporting of statistically significant outcomes between IPD and AD meta-
analyses [2]. However, the observed difference might be only due to the different 
17
statistical approaches usually taken in IPD meta-analyses [22]. Unlike previous studies, 
we directly compared the effect estimates between studies with and without IPD 
contribution, and showed there was no consistent evidence of data availability bias. 
Evidence users may be interested in the discrepancy between the IPD meta-analysis of 
C-RCTs and AD meta-analysis of all available studies as those are the measures 
presented in papers. However, logically speaking, the ROR of IPD meta-analysis of C-
RCTs to AD meta-analysis of all RCTs should be even closer to the unity than the ROR 
of IPD meta-analysis of C-RCTs to AD meta-analysis of NC-RCTs that was examined 
in this study. Given the nonsignificant results of our findings, we expect the difference 
between the IPD meta-analysis of C-RCTs and AD meta-analysis of the whole evidence 
would be small.
 Although we found that significantly more RCTs contributing IPD performed adequate 
allocation concealment to prevent selection bias that could lead to an overestimation of 
the intervention effect compared with RCTs not contributing IPD, we could not detect 
data availability bias in efficacy estimates [23]. A possible explanation for this finding 
is that most outcomes assessed in this study were objective. A previous study that 
examined the effects of inadequate allocation concealment on the effect estimates of 
interventions reported there had been little evidence of bias due to inadequate allocation 
concealment if a trial adopted objective outcomes [24]. Our findings resemble the 
previous report; however, the mechanism of this observation was not explained 
sufficiently. Another explanation might be that other risk of bias domains than 
allocation concealment may yield unbiased results for C-RCTs, and may cancel out the 
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data availability bias. Publication bias or outcome reporting bias might also hide the 
impact of availability bias. 
 Overall, no general tendency for data availability bias was observed, however, this 
does not mean “no data availability bias” for each SR. Although the I2 observed was not 
substantial (<50%), that might be partly due to a small number of NC-RCTs included in 
a single SR [25]. The 95% prediction interval was somewhat wide for the combined 
ROR, which suggested the possible heterogeneity among SRs. Indeed, C-RCTs reported 
significantly larger effect estimates than NC-RCTs in Emberson 2014 [19]; in turn, C-
RCTs reported almost half of the OR which NC-RCTs reported in De Luca 2011 [18]. 
In future IPD-meta-analyses, reviewers need to examine if such extreme unbalance in 
effect estimates may be present between C-RCTs and NC-RCTs in their own reviews.
Strengths and limitations of the study
 This study has several strengths. This is the first study that assessed the data 
availability bias quantitatively. As there has been a push to share clinical trial data in 
many journals and registrations recently, the current study will be useful in 
understanding current data availability and its impact on effect estimates in IPD meta-
analysis. Also, we conducted comprehensive search and rigorous selection of the 
eligible SRs with IPD meta-analysis and confirmed the robustness of the results using 
several statistical analyses. Both unadjusted and adjusted analysis showed that a 
positive result of the primary outcome of RCTs did not appear to affect IPD 
contribution. The direction or strength of the study findings may not be associated with 
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the authors’ willingness to share the data in any category. Moreover, our detailed data 
extraction identified RCT features associated with IPD contribution. Readers of IPD 
meta-analyses would consider that RCTs contributing IPD and those not contributing 
IPD could be different in terms of a year of publication, number of participants, IF and 
adequate allocation concealment.
 However, we should acknowledge several weaknesses. First, ROR in AD meta-
analyses of C-RCTs to those in AD meta-analyses of NC-RCTs is a surrogate measure 
of availability bias. Data availability bias in the true effect estimates should ideally have 
been assessed using IPD from both RCTs that contributed IPD and those did not. 
However, it was infeasible to obtain IPD from RCTs that did not contribute the IPD to 
the SR. We used AD meta-analytic results to detect data availability bias because, it was 
previously reported that most results of IPD meta-analysis agreed with those of AD 
meta-analysis [2]. Thus, IPD of NC-RCTs may not affect the results derived from AD 
of NC-RCTs even if it was available. We also added a sensitivity analysis that 
compared IPD meta-analytic results of RCTs contributing IPD and AD meta-analytic 
results of RCTs not contributing to IPD, and showed a consistent result. 
Second, we chose a dichotomous outcome from each SR measured as a pooled RR or 
OR to calculate ROR. As we needed to mathematically align the direction of 
intervention effect estimates and as the OR calculated for favorable events is 
reciprocally related to that which is calculated for unfavorable events, we adopted ROR 
to assess data availability bias [26]. Although this selection was not likely to confound 
the association between the efficacy and IPD contribution, further studies using other 
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outcome measures such as a difference in standardized mean differences for continuous 
variables would be required. 
Thirdly, our study was possibly underpowered to detect the statistically significant 
difference. We intentionally retrieved all published SRs with pairwise IPD meta-
analysis of interventional RCTs after 2011, because we aimed to obtain data from 
properly conducted SRs after the PRISMA reporting guideline was disseminated [15]. 
Thereby, having a threshold of a statistical significance using p-value < 0.05 in the 
pooled analysis might have had only low power to assess the data availability bias, 
given the limited number of SRs with IPD meta-analysis.
Lastly, our evidence may not be applied to the IPD meta-analyses of non-RCTs that 
are known to have a low IPD retrieval rate [10]. This issue should be investigated in 
future research. 
Conclusion
 Higher quality RCTs tended to contribute IPDs than lower quality RCTs. However, we 
found no consistent evidence of data availability bias in recent IPD meta-analyses. This 
does not mean the absence of availability bias in each and every single IPD meta-
analysis. Further work that uses other effect measures such as subjective outcomes or 
continuous outcomes or that incorporates IPD meta-analyses of non-RCTs is warranted. 
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Figure 1. Flow diagram of the present study
Abbreviations: IPD, individual participant data; RCT, randomized controlled trial; SR, 
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Figure 2. Comparison of treatment effect estimates between studies providing IPD or 
not
Difference in treatment effect estimates is expressed as ROR. An ROR <1 indicates 
larger treatment effect estimates in studies contributing IPD. Abbreviations: IPD, 
individual participant data; ROR, ratio of odds ratio
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・ Trial-level characteristics such as a recent year of publication, large number of 
participants, high impact factor, and adequate allocation concealment were 
independently associated with individual participant data (IPD) contribution to 
systematic reviews (SRs) with IPD meta-analyses. 
・ We could not find consistent evidence of a data availability bias; the effect 
estimates of trials contributing IPD were not statistically different from those not 
contributing IPD in the same systematic reviews (SRs).
What this study adds to what was known?
・ Methodological qualities of trials were associated with the contribution of IPD to 
IPD meta-analysis, but effect estimates might not affect this result.
・ While previous studies suggested the presence of a data availability bias only 
narratively or theoretically, we systematically compared the effect estimates 
between studies with and without IPD contribution and showed that there was no 
consistent evidence of a data availability bias.
What is the implication and what should change now?
 Investigators should be aware of the differences in methodological qualities 
between RCTs with and without IPD contribution when conducting IPD meta-
analyses.
 While we did not detect any systematic data availability bias in the recednt IPD 
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To assess trial-level factors associated with the contribution of individual 
participant data (IPD) to IPD meta-analyses, and to quantify the data 
availability bias, namely the difference between the effect estimates of 
trials contributing IPD and those not contributing IPD in the same 
systematic reviews (SRs).
Design and Setting
We included SRs of randomized controlled trials (RCTs) with IPD meta-
analyses since 2011. We extracted trial-level characteristics and examined 
their association with IPD contribution. To assess the data availability bias, 
we retrieved odds ratios from the original RCT papers, calculated the ratio 
of odds ratios (RORs) between aggregate data (AD) meta-analyses of 
RCTs contributing IPD and those of RCTs not contributing IPD for each 
SR, and meta-analytically synthesized RORs. 
Results
Of 728 eligible RCTs included in 31 SRs, 321 (44%) contributed IPD, 






























































participants, adequate allocation concealment, and impact factor ≥10 were 
associated with IPD contribution. We found the SRs yielded widely 
different estimates of RORs. Overall, there was no significant difference in 
the pooled effect estimates of AD meta-analyses between RCTs 
contributing and not contributing IPD (ROR 1.01, 95% confidence interval 
0.86–1.19). 
Conclusions
There was no consistent evidence of a data availability bias in recent IPD 
meta-analyses of RCTs with dichotomous outcomes. Higher 
methodological qualities of trials were associated with IPD contribution. 
Keywords
Individual participant data, systematic review, meta-analysis, data availability bias
What is new?
Key findings
・ Trial-level characteristics such as a recent year of publication, large number of 
participants, high impact factor, and adequate allocation concealment were 
independently associated with individual participant data (IPD) contribution to 
systematic reviews (SRs) with IPD meta-analyses. 






























































estimates of trials contributing IPD were not statistically different from those not 
contributing IPD in the same systematic reviews (SRs).
What this study adds to what was known?
・ Methodological qualities of trials were associated with the contribution of IPD to 
IPD meta-analysis, but effect estimates might not affect this result.
・ While previous studies suggested the presence of a data availability bias only 
narratively or theoretically, we systematically compared the effect estimates 
between studies with and without IPD contribution and showed that there was no 
consistent evidence of a data availability bias.
What is the implication and what should change now?
 Investigators should be aware of the differences in methodological qualities 
between RCTs with and without IPD contribution when conducting IPD meta-
analyses.
 While we did not detect any systematic data availability bias in the recednt IPD 
meta-analyses, effect estimates in some IPD meta-analyses might still be biased in 
either direction due to the data availability.
Background
 Individual participant data (IPD) meta-analyses are considered to increase the 






























































analyses, in comparison with meta-analyses that are based on aggregate data (AD) 
extracted from published trial reports [1-3]. Encouragement to share IPD from clinical 
studies has risen in the scientific literature, and the number of SRs with IPD meta-
analyses has increased dramatically over the past few years [4-9]. 
 However, SRs with IPD meta-analyses require the review authors to spend substantial 
time and effort to contact and request IPD from the authors of the original studies [1, 
10, 11] with no certainty that all original authors will contribute their data. Indeed, only 
25% of the 760 IPD meta-analyses conducted between 1987 and 2015 retrieved 100% 
of the data from the relevant trials, and 43% retrieved 80% of the data of relevant trials 
[10].
The risk of data availability bias increases when all IPD data cannot be procured [2, 
10, 12, 13]. The data sharing policy of RCTs might be influenced by the views of the 
investigators, as well as by the resources or results of the RCTs [5]. If unavailability of 
IPD is associated with the direction or the size of the intervention effect, studies that are 
available for IPD analyses may not be representative of the whole evidence, and the 
results of such IPD meta-analyses may be misleading. However, the difference in 
characteristics between RCTs contributing and not contributing IPD has not been 
investigated. 
 To date, data availability bias has been discussed only anecdotally, narratively or 
theoretically and there has been no systematic examination aiming to quantify the 
impact of this bias on the effect estimates of meta-analyses [2, 6, 10, 13, 14]. The 
purposes of this study were, therefore, two-fold: (i) To assess RCT-level factors 
associated with the contribution of IPD, and (ii) to examine data availability bias in IPD 


































































All therapeutic RCTs included in SRs that fulfilled all following criteria were eligible: 
(i) SRs with IPD meta-analyses, (ii) SRs that included only RCTs comparing an active 
intervention against a control condition in terms of a dichotomous outcome, (iii) SRs 
that reported a full reference list of the included RCTs, and (iv) SRs published in 
English. We excluded the following SRs: (v) SRs published before 2011, (vi) SRs 
where all included RCTs provided IPD data, (vii) SRs of diagnostic or prognostic 
studies, and (viii) SRs with network meta-analyses. A cutoff year of 2011 was selected 
because a reporting guideline for SRs, Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses: The PRISMA Statement, was first published in 2009 [15]. 
We allowed two years for the dissemination of this guideline.
Search methods
We used the reference list from a recent comprehensive review of IPD meta-analyses 
conducted by Nevitt et al[10]. We also performed an updated search of MEDLINE via 
Ovid using the same search strategy as the above review to identify relevant SRs as of 































































　Two pairs of researchers (YT-TF and KO-AO) independently screened the titles and 
abstracts of articles identified by the updated search. We pooled the potentially eligible 
SRs and the reference list from the review conducted by Nevitt et al [10]. We then 
independently assessed eligibility based on a full-text review.
Data extraction
　Eight researchers (YT, TF, KO, AO, ST, TI, YL and CP) independently extracted the 
following RCT-level factors from the included RCTs; year of publication, sample size, 
whether the primary outcomes of the RCT was positive or not, allocation concealment, 
industrial sponsorship, publication status (full-publication or not), data sharing 
statement (available, unavailable, or unclear), journal impact factor (IF), and language. 
We selected the primary outcomes of the RCTs using the following hierarchy: an 
outcome that was mentioned (1) as primary, (2) in the title, (3) in the objective, (4) first 
in the abstract, (5) first in the text. We defined the primary outcome as positive when 
the selected primary outcome was statistically significant in superiority trials or within 
the noninferiority margin in noninferiority trials. We chose not blinding but adequate 
allocation concealment as a marker of study quality because the feasibility of blinding 






























































journal from 2017 Journal Citation Reports® Science Edition (Thomson Reuters, 2018) 
and assigned an IF of zero to conference abstracts and unpublished studies. 
 We also extracted the following SR-level factors from the included SRs: year of 
publication, the number of included RCTs, types of review (pharmacological or non-
pharmacological interventions, adult or pediatric, and Cochrane or non-Cochrane), and 
funding (yes/no).
 To examine any discrepancy between the effect estimates of RCTs contributing IPD 
(C-RCTs) and those not contributing IPD (NC-RCTs), we selected a single outcome per 
SR. As the SR might have reported several outcomes, we selected the single primary 
outcome that fulfilled all the following criteria: (1) An efficacy outcome measured as a 
pooled risk ratio (RR) or odds ratio (OR), (2) Not a composite outcome, and (3) Not an 
outcome of adverse events or subgroup analysis. We did not adopt a composite outcome 
because the definition or components of the outcome was expected to vary across trials. 
In cases where the primary outcome did not meet these criteria, we adopted the outcome 
with the largest number of trials or the first outcome described which met these criteria.
　For the single selected outcome in each SR, we extracted the number of events and 
participants in the intervention and control groups from the original published journal 
articles or conference abstracts of both C-RCTs and NC-RCTs. If the number of events 
or participants was missing, or if the selected outcome was not reported in the original 
RCT but provided in the IPD meta-analysis, we imputed them from the information or 
outcome data presented in the IPD-SR. We also extracted the pooled RR or OR from 
the reported IPD meta-analysis. We converted the pooled RR to OR using the observed 































































We first described RCT characteristics, each classified by whether the RCT contributed 
IPD to the SR or not. We then explored the RCT-level factors (see Data Extraction) 
associated with the contribution of IPD using univariable mixed-effect logistic 
regression with a random intercept for SRs to account for the clustering effects of RCTs 
within each SR, and a multivariable mixed-effects logistic regression model with fixed 
factors (year of publication, sample size, positive primary outcome [yes or no], adequate 
allocation concealment [yes or no], industrial sponsorship [yes or no], publication status 
[full-publication or not], data sharing statement [available or not), IF [no IF, < 5, 5 ≤ to 
< 10, or 10 ≤], language [published in English or not] ), and a random intercept for SRs. 
 We calculated odds ratios using the number of events and the number of patients 
aggregated from the original RCT papers and pooled them in aggregate data (AD) meta-
analyses using random-effects models. Each OR was recalculated so that an OR <1 
indicated that the intervention arm was favored. To assess data availability bias 
quantitatively, we calculated and pooled the ratio of odds ratios (ROR) in AD meta-
analyses of C-RCTs to those in AD meta-analyses of NC-RCTs using the following 
two-step approach proposed by Sterne et al [17]. First, we estimated an ROR in each 
AD meta-analysis by using a random-effect meta-regression. An ROR <1 indicated a 
larger treatment effect estimate in AD meta-analyses of C-RCTs than in NC-RCTs. We 






























































random-effects meta-analysis model. We used the I2 statistic, τ2 –statistic and 95% 
prediction interval to quantify the heterogeneity between SRs. 
We expressed continuous variables as mean (standard deviation) for normally 
distributed data or median (interquartile range [IQR]) for non-normally distributed data 
and categorical variables as numbers with the percentage. We considered a two-sided p 
value < 0.05 as a statistically significant difference. We used Stata/SE, V.14.0  
(StataCorp, College Station, TexasX, USA) for all analyses.
Sensitivity analysis
 To examine the robustness of the estimated ROR, we performed the following 
sensitivity analyses. First, we adjusted SR-level factors (year of publication, the number 
of included studies, types of review [Cochrane or non-Cochrane, pharmacological or 
not, and pediatric or not], or funding) that assumed to be confounders of the association 
between IPD contribution and the ROR using the meta-regression model. Second, we 
excluded RCTs for which we imputed the results of AD meta-analysis with those 
reported in IPD meta-analysis. Third, we examined a discrepancy between IPD meta-
analytic results of C-RCTs and AD meta-analytic results of NC-RCTs using the same 































































As a post-hoc analysis, we used log-transformed data of the number of randomized 
participants and impact factors instead of categorized data, and added them into the 
mixed effects multivariable model to examine their associations with the contribution of 
IPD. 
The study was registered in UMIN-CTR as UMIN000028325 
(https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000036147). 
Results
Results of searches 
 Figure 1 shows the flow diagram of the present study. We identified 2349 possible 
SRs with IPD meta-analyses including 102 references from the previous study [10]. We 
assessed the eligibility of 268 SRs with IPD meta-analyses that remained after screening 
of titles and abstracts, and included 37 IPD-SRs for a total of 728 RCTs. For the 
assessment of data availability bias, six SRs had only one or two RCTs that reported the 
selected outcome, which made it impossible to calculate the ROR using a random 
effects meta-regression model. Among 631 RCTs included in the remaining 31 SRs, 
264 did not report the selected outcome. Consequently, we included 367 RCTs that 






























































Characteristics of included IPD systematic reviews
Supplementary file 2 shows the characteristics of the included IPD-SRs. The number of 
included RCTs in the IPD-SRs varied from 5 to 103 (median 13, IQR 11 to 21), and the 
IPD retrieval rate ranged from 10 % to 92 % (median 71 %, IQR 50 % to 81 %). 
Twenty-five (68 %) IPD-SRs had funding, 21 (57 %) focused on pharmacological 
interventions, 7 (19%) were Cochrane reviews, and 2 (5 %) were in pediatric areas. 
Characteristics of included studies and IPD contribution
 Of 728 RCTs included, 321 contributed IPD and 407 did not. Table 1 summarizes the 
characteristics of the included RCTs and the association with the IPD contribution. C-
RCTs were likely to have a recent year of publication, a larger sample size, adequate 
allocation concealment, full publication status, higher impact factor, and sponsorships 
as compared to NC-RCTs. We next examined the association between RCT 
characteristics and IPD contribution with logistic regressions. As shown in Table 1, a 
recent publication year, larger number of participants randomized, adequate allocation 
concealment, and high impact factor (≥10) compared to IF <5 were independently 
associated with IPD contribution. On the other hand, whether the primary outcomes 
were positive was not associated with IPD contribution (adjusted OR 1.06, 95% CI 0.72 
to 1.55). The association of the number of randomized participants or that of impact 
factors with IPD contribution remained unchanged when we used log-transformed data 































































Table 1 Characteristics of included RCTs and the associations with IPD contribution




Years since publication, mean (SD) 10.0 (6.9) 11.4 (8.9) 0.94 (0.92 to 0.97) 0.96 (0.93 to 0.99)
Number of randomized participants
  1st quartile 12 to 101 5 to 60 Ref Ref
  2nd quartile 102 to 228 60 to 115 1.85 (1.12 to 3.06) 1.54 (0.90 to 2.63)
  3rd quartile 228 to 619 116 to 250 2.89 (1.71 to 4.90) 1.90 (1.07 to 3.37)
  4th quartile 620 to 20536 250 to 17354 5.09 (2.83 to 9.15) 2.28 (1.16 to 4.47)
Adequate allocation concealment 230 (57) 107 (33) 3.34 (2.27 to 4.91) 2.33 (1.53 to 3.55)
Publication status
  Full publication 375 (92) 281 (88) Ref Ref
  Conference abstract 23 (6) 35 (10) 0.37 (0.9 to 0.71) 0.82 (0.27 to 2.51)
  Unpublished 9 (2) 5 (2) 0.66 (0.18 to 2.38) n/a‡
Impact factor§
  <5 142 (35) 161 (50) Ref Ref
  ≥5 to <10 66 (16) 42 (13) 1.57 (0.93 to 2.65) 1.52 (0.87 to 2.65)
  ≥10 152 (37) 48 (15) 3.13 (1.86 to 5.24) 2.18 (1.22 to 3.88)
  No impact factor 47 (12) 70 (22) 0.59 (0.35 to 1.00) 0.84 (0.33 to 2.14)
Industrial sponsorship 119 (29) 68 (21) 2.13 (1.32 to 3.45) 1.40 (0.84 to 2.34)
Published in English 399 (98) 307 (96) 2.29 (0.77 to 6.81) 0.99 (0.26 to 3.81)
Statement to share the data 4 (1) 3 (1) 1.03 (0.19 to 5.56) 0.61 (0.10 to 3.80)
Positive results in the primary 
outcome‖‖ 216 (55) 148 (47) 1.16 (0.82 to 1.66) 1.06 (0.72 to 1.55)
Note: Values for categorical variables and continuous variables are given as number (percentage) and mean (SD) 
or median (IQR). *Using univariable mixed effects logistic regression with a random intercept for the systematic 
review. †Using multivariable mixed effects logistic regression model with fixed factors (year of publication, 
sample size, adequate allocation concealment, publication status (full-publication or not), impact factor (no 
impact factor, < 5, 5 ≤ to < 10, or 10 ≤), industrial sponsorship, language (written in English or not), data sharing 
statement (available or not) and whether the primary outcomes in the RCTs were positive) and a random intercept 
for the systematic review. ‡No sufficient data was available to conduct the multivariable analysis §Impact factor 
in 2017. We assigned an impact factor of zero to conference abstracts and unpublished studies. ‖‖Any of the 
primary outcomes were positive when the selected primary outcome was statistically significant in efficacy trials 
or within the noninferiority margin in noninferiority trials. Abbreviations: RCT, randomized controlled trial; IPD, 
individual participant data; C-RCT, RCTs contributing IPD; NC-RCT, RCTs not contributing IPD; SD, standard 
deviation; IQR, interquartile range.
Data availability bias
 Figure 2 shows the RORs that compared AD meta-analyses of C-RCTs and those of 
NC-RCTs among 31 SRs including 377 RCTs. We found the SRs yielded widely 






























































treatment effect in C-RCTs compared with NC-RCTs [18], whereas one SR showed a 
significantly small effect of C-RCTs compared with NC-RCTs [19]. The remaining 29 
SRs showed a non-significant difference in treatment effects between C-RCTs and NC-
RCTs. Overall, we found no statistically significant association between IPD 
contribution and the size or direction of treatment effects which could be estimated from 
AD meta-analyses of the trials within each SR (pooled ROR 1.01, 95 % CI 0.86 to 1.19, 
I2 = 27 %, τ2 = 0.044, and 95% prediction interval 0.60 to 1.42) (Fig 2). 
Sensitivity analyses
A sensitivity analysis excluding the data imputed from the IPD meta-analysis showed a 
consistent result (pooled ROR 1.02, 95% CI 0.85 to 1.22, I2 = 34 %, τ2 = 0.064, and 
95% prediction interval 0.52 to 1.51). The univariable meta-regression analyses showed 
that there were no statistically significant associations between any of the SR-level 
factors and the ROR (Supplementary file 3). There was no statistically significant 
difference between IPD meta-analytic results of C-RCTs and AD meta-analytic results 
of NC-RCTs (ROR 1.11, 95% CI 0.83 to 1.48, I2 = 47 %, τ2 = 0.132, and 95% 
































































 RCT features reflecting the high methodological quality of RCTs, such as a large 
number of participants, IF ≥ 10, and adequate allocation concealment, were 
independently associated with IPD contribution. However, we could not find consistent 
evidence of data availability bias due to IPD contribution in recent SRs with IPD meta-
analyses. 
Context with prior studies
 Our findings of the RCT characteristics associated with IPD sharing are mostly in line 
with those from previous studies in the literature. We found that low quality RCTs, that 
had unclear or high risk of bias in participant selection and had lower impact, might be 
less likely to provide IPD. A previous research reported a higher prevalence of apparent 
errors, i.e. low quality, in the reporting of statistical results was associated with authors’ 
reluctance to share research data in high-ranked psychology journals [20]. In addition, 
old studies might not provide IPD due to limited access to the trial data [21]. These 
previous findings, however, were based on a univariable analysis. We comprehensively 
investigated the RCT factors associated with data sharing and examined if the study 
quality made an independent contribution using a multivariable model. Our data also 
showed that such trends persisted in more recent cohorts.
 Previous studies have raised concerns about data availability bias in effect estimates of 
meta-analyses using IPD. [2, 10, 13]. For example, a prior study showed a discrepancy 
of 20% in reporting of statistically significant outcomes between IPD and AD meta-






























































statistical approaches usually taken in IPD meta-analyses [22]. Unlike previous studies, 
we directly compared the effect estimates between studies with and without IPD 
contribution, and showed there was no consistent evidence of data availability bias. 
Evidence users may be interested in the discrepancy between the IPD meta-analysis of 
C-RCTs and AD meta-analysis of all available studies as those are the measures 
presented in papers. However, logically speaking, the ROR of IPD meta-analysis of C-
RCTs to AD meta-analysis of all RCTs should be even closer to the unity than the ROR 
of IPD meta-analysis of C-RCTs to AD meta-analysis of NC-RCTs that was examined 
in this study. Given the nonsignificant results of our findings, we expect the difference 
between the IPD meta-analysis of C-RCTs and AD meta-analysis of the whole evidence 
would be small.
 Although we found that significantly more RCTs contributing IPD performed adequate 
allocation concealment to prevent selection bias that could lead to an overestimation of 
the intervention effect compared with RCTs not contributing IPD, we could not detect 
data availability bias in efficacy estimates [23]. A possible explanation for this finding 
is that most outcomes assessed in this study were objective. A previous study that 
examined the effects of inadequate allocation concealment on the effect estimates of 
interventions reported there had been little evidence of bias due to inadequate allocation 
concealment if a trial adopted objective outcomes [24]. Our findings resemble the 
previous report; however, the mechanism of this observation was not explained 
sufficiently. Another explanation might be that other risk of bias domains than 






























































data availability bias. Publication bias or outcome reporting bias might also hide the 
impact of availability bias. 
 Overall, no general tendency for data availability bias was observed, however, this 
does not mean “no data availability bias” for each SR. Although the I2 observed was not 
substantial (<50%), that might be partly due to a small number of NC-RCTs included in 
a single SR [25]. The 95% prediction interval was somewhat wide for the combined 
ROR, which suggested the possible heterogeneity among SRs. Indeed, C-RCTs reported 
significantly larger effect estimates than NC-RCTs in Emberson 2014 [19]; in turn, C-
RCTs reported almost half of the OR which NC-RCTs reported in De Luca 2011 [18]. 
In future IPD-meta-analyses, reviewers need to examine if such extreme unbalance in 
effect estimates may be present between C-RCTs and NC-RCTs in their own reviews.
Strengths and limitations of the study
 This study has several strengths. This is the first study that assessed the data 
availability bias quantitatively. As there has been a push to share clinical trial data in 
many journals and registrations recently, the current study will be useful in 
understanding current data availability and its impact on effect estimates in IPD meta-
analysis. Also, we conducted comprehensive search and rigorous selection of the 
eligible SRs with IPD meta-analysis and confirmed the robustness of the results using 
several statistical analyses. Both unadjusted and adjusted analysis showed that a 
positive result of the primary outcome of RCTs did not appear to affect IPD 






























































the authors’ willingness to share the data in any category. Moreover, our detailed data 
extraction identified RCT features associated with IPD contribution. Readers of IPD 
meta-analyses would consider that RCTs contributing IPD and those not contributing 
IPD could be different in terms of a year of publication, number of participants, IF and 
adequate allocation concealment.
 However, we should acknowledge several weaknesses. First, ROR in AD meta-
analyses of C-RCTs to those in AD meta-analyses of NC-RCTs is a surrogate measure 
of availability bias. Data availability bias in the true effect estimates should ideally have 
been assessed using IPD from both RCTs that contributed IPD and those did not. 
However, it was infeasible to obtain IPD from RCTs that did not contribute the IPD to 
the SR. We used AD meta-analytic results to detect data availability bias because, it was 
previously reported that most results of IPD meta-analysis agreed with those of AD 
meta-analysis [2]. Thus, IPD of NC-RCTs may not affect the results derived from AD 
of NC-RCTs even if it was available. We also added a sensitivity analysis that 
compared IPD meta-analytic results of RCTs contributing IPD and AD meta-analytic 
results of RCTs not contributing to IPD, and showed a consistent result. 
Second, we chose a dichotomous outcome from each SR measured as a pooled RR or 
OR to calculate ROR. As we needed to mathematically align the direction of 
intervention effect estimates and as the OR calculated for favorable events is 
reciprocally related to that which is calculated for unfavorable events, we adopted ROR 
to assess data availability bias [26]. Although this selection was not likely to confound 






























































outcome measures such as a difference in standardized mean differences for continuous 
variables would be required. 
Thirdly, our study was possibly underpowered to detect the statistically significant 
difference. We intentionally retrieved all published SRs with pairwise IPD meta-
analysis of interventional RCTs after 2011, because we aimed to obtain data from 
properly conducted SRs after the PRISMA reporting guideline was disseminated [15]. 
Thereby, having a threshold of a statistical significance using p-value < 0.05 in the 
pooled analysis might have had only low power to assess the data availability bias, 
given the limited number of SRs with IPD meta-analysis.
Lastly, our evidence may not be applied to the IPD meta-analyses of non-RCTs that 
are known to have a low IPD retrieval rate [10]. This issue should be investigated in 
future research. 
Conclusion
 Higher quality RCTs tended to contribute IPDs than lower quality RCTs. However, we 
found no consistent evidence of data availability bias in recent IPD meta-analyses. This 
does not mean the absence of availability bias in each and every single IPD meta-
analysis. Further work that uses other effect measures such as subjective outcomes or 































































SR, systematic review; IPD, individual participant data; AD, aggregated data; RCT, 
randomized controlled trial; IF, impact factor; RR, risk ratio; OR, odds ratio; ROR, ratio 
of odds ratio; CI, confidence interval; IQR, interquartile range; 
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Figure titles and legends
Figure 1. Flow diagram of the present study
Abbreviations: IPD, individual participant data; RCT, randomized controlled trial; SR, 































































Figure 2. Comparison of treatment effect estimates between studies providing IPD or 
not
Difference in treatment effect estimates is expressed as ROR. An ROR <1 indicates 
larger treatment effect estimates in studies contributing IPD. Abbreviations: IPD, 
individual participant data; ROR, ratio of odds ratio
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Supplementary file 1. Search strategy of the present study
1. (individual patient$ adj6 data).ti,ab. 
2. (individual patient$ adj6 report$).ti,ab. 
3. (individual patient$ adj6 outcome$).ti,ab. 
4. (individual patient$ adj6 level$).ti,ab. 
5. individual participant data.ti,ab. 
6. ipd.ti,ab. 
7. (individual subject$ adj6 data).ti,ab. 
8. (individual subject$ adj6 report$).ti,ab. 
9. (individual subject$ adj6 outcome$).ti,ab. 
10. (individual subject$ adj6 level$).ti,ab. 
11. (raw patient$ adj6 data).ti,ab. 
12. (raw patient$ adj6 report$).ti,ab. 
13. (raw patient$ adj6 outcome$).ti,ab. 
14. (raw patient$ adj6 level$).ti,ab. 
15. (raw subject$ adj6 data).ti,ab. 
16. (raw subject$ adj6 report$).ti,ab. 
17. (raw subject$ adj6 outcome$).ti,ab. 
18. (raw subject$ adj6 level$).ti,ab. 
19. idiopathic.ti,ab. 
20. immediate pigment darkening.ti,ab. 
21. intermittent peritoneal dialysis.ti,ab. 
22. invasive pneumococcal disease.ti,ab. 
23. indirect photometric detection.ti,ab. 
24. interaural phase disparity.ti,ab. 
25. or/1-18 
26. or/19-24 
27. 25 not 26 
28. limit 27 to ed=20140611-20180310 
